ID   H-MESO-1
AC   CVCL_5759
SY   H-Meso-1; HMESO-1; HMeso-1; HMeso1; HMESO1; H-Meso; HMESO; HMeso; Hmeso; MM-E1
DR   BTO; BTO_0005907
DR   BioSamples; SAMEA100968
DR   cancercelllines; CVCL_5759
DR   CLS; 300186
DR   Cosmic; 922059
DR   Cosmic; 1522785
DR   Cosmic; 1541215
DR   GEO; GSM726268
DR   NCI-DTP; H-MESO-1
DR   Progenetix; CVCL_5759
DR   Wikidata; Q54871890
RX   PubMed=3496960;
RX   PubMed=3555770;
RX   PubMed=10373640;
RX   PubMed=21454801;
RX   PubMed=21642991;
RX   PubMed=28159921;
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=21642991).
CC   Transformant: ChEBI; CHEBI_46661; Asbestos.
CC   Omics: Variations; SNP array analysis.
CC   Caution: Indicated as originating from a 35 year old male patient in PubMed=3555770 and from a 42 year old male patient in PubMed=3496960.
CC   Caution: It seems that PubMed=10373640 has renamed this cell line as MM-E1 because they thought it has a have an epithelial morphology.
CC   Derived from site: In situ; Lung, pleura; UBERON=UBERON_0000977.
ST   Source(s): CLS=300186
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 11
ST   D16S539: 12
ST   D18S51: 14,20
ST   D21S11: 30,33.2
ST   D3S1358: 14
ST   D5S818: 10,12
ST   D7S820: 12
ST   D8S1179: 10
ST   FGA: 23
ST   Penta D: 11,13
ST   Penta E: 7,11
ST   TH01: 6,9.3
ST   TPOX: 8
ST   vWA: 17
DI   NCIt; C45665; Pleural biphasic mesothelioma
DI   ORDO; Orphanet_50251; Pleural mesothelioma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   35Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 27
//
RX   PubMed=3496960;
RA   Griffin T.W., Richardson C., Houston L.L., LePage D., Bogden A.,
RA   Raso V.A.;
RT   "Antitumor activity of intraperitoneal immunotoxins in a nude mouse
RT   model of human malignant mesothelioma.";
RL   Cancer Res. 47:4266-4270(1987).
//
RX   PubMed=3555770;
RA   Reale F.R., Griffin T.W., Compton J.M., Graham S., Townes P.L.,
RA   Bogden A.;
RT   "Characterization of a human malignant mesothelioma cell line (H-MESO-1):
RT   a biphasic solid and ascitic tumor model.";
RL   Cancer Res. 47:3199-3205(1987).
//
RX   PubMed=10373640; DOI=10.3892/ijmm.4.1.67;
RA   Scarpa S., Giuffrida A., Fazi M., Coletti A., Palumbo C., Pass H.I.,
RA   Procopio A., Modesti A.;
RT   "Migration of mesothelioma cells correlates with histotype-specific
RT   synthesis of extracellular matrix.";
RL   Int. J. Mol. Med. 4:67-71(1999).
//
RX   PubMed=21454801; DOI=10.1165/rcmb.2010-0282OC; PMCID=PMC3262687;
RA   Shukla A., Barrett T.F., MacPherson M.B., Hillegass J.M.,
RA   Fukagawa N.K., Swain W.A., O'Byrne K.J., Testa J.R., Pass H.I.,
RA   Faux S.P., Mossman B.T.;
RT   "An extracellular signal-regulated kinase 2 survival pathway mediates
RT   resistance of human mesothelioma cells to asbestos-induced injury.";
RL   Am. J. Respir. Cell Mol. Biol. 45:906-914(2011).
//
RX   PubMed=21642991; DOI=10.1038/ng.855; PMCID=PMC4643098;
RA   Bott M.J., Brevet M., Taylor B.S., Shimizu S., Ito T., Wang L.,
RA   Creaney J., Lake R.A., Zakowski M.F., Reva B., Sander C., Delsite R.,
RA   Powell S.N., Zhou Q., Shen R.-L., Olshen A.B., Rusch V.W., Ladanyi M.;
RT   "The nuclear deubiquitinase BAP1 is commonly inactivated by somatic
RT   mutations and 3p21.1 losses in malignant pleural mesothelioma.";
RL   Nat. Genet. 43:668-672(2011).
//
RX   PubMed=28159921; DOI=10.18632/oncotarget.14907; PMCID=PMC5470978;
RA   Masuelli L., Benvenuto M., Di Stefano E., Mattera R., Fantini M.,
RA   De Feudis G., De Smaele E., Tresoldi I., Giganti M.G., Modesti A.,
RA   Bei R.;
RT   "Curcumin blocks autophagy and activates apoptosis of malignant
RT   mesothelioma cell lines and increases the survival of mice
RT   intraperitoneally transplanted with a malignant mesothelioma cell
RT   line.";
RL   Oncotarget 8:34405-34422(2017).
//